Clinical Trials

LymphoidOther hematologic neoplasm

12 enrolled

Burkitt Lymphoma, Leukemia, Lymphoma, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT07398638 2026-02-10

Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study

Phase 1/2 Not yet recruiting

122 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06594939 2026-02-04

Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

31 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT07365306 2026-01-26

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

43 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT07310186 2025-12-30

Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy

200 enrolled

Phase 1 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse

NCT07225439 2025-11-06

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

15 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07197307 2025-09-29

CLEAR

120 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT07168291 2025-09-17

Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma

3 enrolled

Phase 1/2 Not yet recruiting

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT07159906 2025-09-08

Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

62 enrolled

Phase 1/2 Not yet recruiting

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT07035379 2025-08-22

A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL

66 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06665217 2025-08-14

G-Pola-ZLP in Diffuse Large B-Cell Lymphoma

80 enrolled

Phase 1 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse

NCT07024147 2025-06-17

JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma

20 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07012980 2025-06-10

Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL

38 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06921044 2025-04-10

A Study of R-mini-MCOP in the Treatment of Elderly, Previously Untreated DLBCL

33 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06867536 2025-03-18

GLOHRT-01

40 enrolled

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT06778902 2025-01-16

Dragon

80 enrolled

LymphoidSarcoma

Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT06748521 2024-12-27

Dynamic CtDNA-guided Targeted Therapy in DLBCL

108 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06734624 2024-12-16

The Microbiome in Blood Cancer and HLH

750 enrolled

LymphoidMyeloid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphohistiocytosis, Hemophagocytic

NCT06669143 2024-11-01

Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission

19 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06656234 2024-10-24

The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study

200 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06652139 2024-10-22

Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive

82 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06652152 2024-10-22

DEL Biomarker

400 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06323447 2024-10-09

PC002

210 enrolled

LymphoidPlasma cell

Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse

NCT06594432 2024-09-19

Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement

40 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06573099 2024-08-27

A Real-World Study on Extranodal Lymphoma

5,000 enrolled

Phase 3 Not yet recruiting

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT06573645 2024-08-27

A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL

428 enrolled

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT06516978 2024-07-24

A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

528 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06441097 2024-06-04

Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

152 enrolled

Phase 2/3 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06355401 2024-04-09

Maintenance Hormonal Therapy and DLBCL

100 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06289959 2024-03-04

Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL

30 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06062641 2023-11-07

Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL

50 enrolled

Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05923502 2023-10-23

(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)

LymphoidOther hematologic neoplasm

200 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, B-Cell, Marginal Zone

NCT05990985 2023-08-18

The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.

20 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05834426 2023-06-22

Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers

50 enrolled

Lymphoma, Non-Hodgkin, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05746858 2023-02-28

MIMOSA

300 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05596097 2022-10-27

Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission

15 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05298293 2022-04-05

EMILY

160 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05280626 2022-03-15

First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP

100 enrolled